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Background: The P2X7 receptor (P2X7-R) is a non-selective adenosine triphosphate-gated cation channel present
in epithelial and immune cells, and involved in inﬂammatory response. Extracellular nucleotides released in con-
ditions of cell stress or inﬂammation may function as a danger signal alerting the immune system from inﬂam-
mation. We investigated the therapeutic action of P2X7-R blockade in a model of inﬂammatory bowel disease.
Methods: Rats with trinitrobenzene sulfonic (TNBS) acid-induced colitis were treated with the P2X7-R antago-
nists A740003 or brilliant blue G (BBG) through intra-peritoneal (IP) or intra-colonic (IC) injection prior to colitis
induction. Clinical and endoscopic follow-up, histological scores, myeloperoxidase activity, densities of collagen
ﬁbers and goblet cells were evaluated. P2X7-R expression, NF-kappa B and Erk activities, and densities of T-cells
and macrophages were analyzed by immunoperoxidase. The inﬂammatory response was determined by mea-
suring inﬂammatory cytokines in cultures of colon explants, by enzyme-linked immunosorbent assay. Colonic
apoptosis was determined by the TUNEL assay. Results: IP-BBG signiﬁcantly attenuated the severity of colitis,
myeloperoxidase activity, collagen deposition, densities of lamina propria T-cells andmacrophages, while main-
taining goblet cell densities. IP-BBG inhibited the increase in P2X7-R expression in parallel with apoptotic rates.
TNF-α and interleukin-1β stabilized in low levels, while TGF-β and interleukin-10 did not change following IP-
BBG-therapy. Colonic NF-kappa-B and Erk activationwere signiﬁcantly lower in IP-BBG-treated animals. Prophy-
lactic IP-A740003 also protected rats against the development of TNBS-colitis. Conclusions: Prophylactic sys-
temic P2X7-R blockade is effective in the prevention of experimental colitis, probably due to a systemic
anti-inﬂammatory action, interfering with a stress-inﬂammation ampliﬁcation loop mediated by P2X7-R.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Crohn's disease (CD) and ulcerative colitis (UC) constitute the two
major formsof inﬂammatory bowel disease (IBD), and are characterized
by chronic and relapsing inﬂammation of the gastrointestinal tract [1,2].
Although the pathogenesis of IBD is rather complex, evidence indicates
the concomitant involvement of genetic predisposition, environmentalPesquisa do Estado do Rio de
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ights reserved.triggers, microbial agents, and immune dysfunction as essential factors
for disease development [3,4]. In CD, a background of persistent mu-
cosal T-cell activation orchestrates an imbalance of inﬂammatory
mediators including cytokines, determining a predominant T helper
cell type 1 (Th1) phenotype [5,6]. In this context, the expression of
pro-inﬂammatory genes and the course of mucosal inﬂammation in
CD are regulated through the activation of nuclear transcription fac-
tor kappa-B (NF-κB) and mitogen-activated protein (MAP) kinases
[7–10].
Nevertheless, in the past few years, several investigations have sug-
gested a critical role for the innate immunity in CD [11]. Notably, the
association of CD with polymorphisms in the nucleotide binding and
oligomerization domain-containing protein 2 (NOD2/CARD15) [12,13],
and also the autophagy-related genes, ATG16L1 [14] and IRGM [15], sup-
ports the idea of abnormal recognition and processing of bacterial com-
ponents as critical elements in the disease pathogenesis. However, the
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individuals with these mutations develops CD. Hence, with respect to
intestinal inﬂammation it is likely that other mechanisms may play ad-
ditional roles and also interact with existing defects.
Purinergic signaling is an important component of host defense
against intracellular pathogens, mainly through activation of P2 recep-
tors, in particular the purinoreceptor P2X7 (P2X7-R) [16]. The P2X7-R
is an extracellular adenosine triphosphate (ATP)-gated cation channel
expressed on epithelial cells and on immune effector cells, and is in-
volved in the regulation of pro-inﬂammatory cytokines such as IL-1β
and IL-18 [17], apoptosis and autophagy induction [18,19], and the
elimination of infectious pathogens [20–22]. Extracellular ATP, released
from infected or stressed cells, has been regarded as an endogenous
signalingmolecule capable of controlling inﬂammation and immune re-
sponses [23,24], T regulatory cell homeostasis and function [25,26], and
regulation of autoimmune disorders [27,28]. In addition, it has been re-
cently demonstrated that the inﬂammasome activation through NLRP3,
a NOD-like receptor (NLR), can be triggered by signals such as bacterial
constituents in the presence of exogenous ATP, through the P2X7-R
associated with pannexin-1 [29,30]. In parallel, polymorphisms of the
NLRP3 gene recently associated with CD [31,32], have contributed to
the increasing interest in the role of inﬂammasomes in the pathogenesis
of IBD.
Taken together, previous ﬁndings from our group showing a site-
speciﬁc modulation of intestinal epithelial P2X7-R, with up-regulation
in response to IFN-γ, and the consequent ATP-induced apoptotic cell
death [18,19,33], appear to implicate P2X7-R in the pathogenesis of
diseases based on immune deregulation. In this regard, we hypothe-
sized that purinergic signaling through the P2X7-R may play an impor-
tant role in regulating intestinal inﬂammatory processes. Therefore, in
the present work, we investigated the potential therapeutic action of
P2X7-R blockade in an experimental model of IBD.
2. Materials and methods
2.1. Animals
Male Wistar rats (each weighing between 250 and 300 g) obtained
from the Animal Care of the Laboratory of Experimental Surgery of the
Federal University of Rio de Janeiro (Rio de Janeiro, RJ, Brazil) were
maintained under speciﬁc pathogen-free conditions in a temperature-
controlled room (24 °C), on a 12-h/12-h light and dark cycle. Standard
laboratory pelleted formula and tap water were provided ad libitum.
Animals were housed in rack-mounted wire cages with 2 animals per
cage.
2.2. Induction of colitis
On day 0, rats were anesthetized subcutaneously with ketamine
(35 mg/kg) and xylazine (5 mg/kg), and colitis was induced by
intracolonic instillation of 1 ml of a solution containing 25 mg of
2,4,6-trinitrobenzene sulfonic (TNBS) acid (Sigma Chemical Co., St.
Louis, MO, USA) in 30% ethanol (Merck, Darmstadt, Germany) using a
4-French catheter (8-cm long) inserted through the rectum, as previ-
ously described [34]. Thereafter, animals were allowed access to stan-
dard chow and water ad libitum.
2.3. Experimental design
After an acclimation period of one week, rats maintained under
speciﬁc pathogen-free conditions were randomly assigned to one
of ﬁve groups of 6–10 animals each. Animals were then tested for
the effects of pre-treatment with P2X7-R blockers on TNBS-
induced colitis. The P2X7-R blockers utilized in this work were
the brilliant blue G (BBG) (Sigma-Aldrich, Saint Louis, MO, USA)
and A740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide]
(Tocris Bioscience, Bristol, UK) [35]. BBG was dissolved in distilled
water and administered at 40 mg/kg. A-740003 was dissolved in dis-
tilled water and 40% hydroxypropyl-β-cyclodextrin at 16 mg/kg. Dur-
ing the whole experiment clinical manifestations such as diarrhea,
bleeding, and weight changes were recorded.
Twenty-four hours prior to colitis induction animals were treated
with intracolonic or intraperitoneal injections of BBG. On day 0, colitis
was induced by the TNBS/ethanol administration. Because BBG half-
life has been shown to be limited in animal models or in vitro [36], on
day 3 rats received a booster of intracolonic or intraperitoneal BBG.
Next, to conﬁrm the prophylactic effect of BBG, a second P2X7-R
blocker, A740003was used through the intraperitoneal route in a single
administration 30 min prior to colitis induction.
For the surgical procedure, animals were anesthetized as previously
described and submitted to a laparotomy under sterile technique. The
distal colonwas removed, opened longitudinally, and rinsedwith saline.
The distal 2–3 cm of the excised colon was cut longitudinally and
horizontally into 4 similar portions. The distal portions were used for
explant cultures, myeloperoxidase activity and protein measurements,
while the proximal portions were used for histologic/morphometric
and immunohistochemistry techniques. A quick death procedure by
cervical dislocation was uniformly performed in all animals on experi-
mental day 7.
2.4. Colonoscopic assessment
On experimental day 7, animals were anesthetized and examined
with a ﬂexible ﬁberscope FB 120P with a diameter of 2.8 mm (Fujinon)
assembled to a video-camera for recording images. The distal 4 cm of
the colon was examined in all experimental animals. Colon injury was
scored by two independent observers using an adapted endoscopic
index of colitis [37,38], considering images obtained at the distal 2 cm.
The following parameters were analyzed and graded as 0 (absent) or
1 (present) each: changes of the vascular pattern; mucosal granularity;
strictures; bleeding; and ulcers (total score ranging from 0 to 5).
2.5. Macroscopic assessment of the colon
Colon injury was evaluated and scored by two independent ob-
servers according to the following macroscopic parameters: adhesion,
strictures, ulcer and thickness of colon wall. For adhesions grading
was considered: 0, absent; 1, light; and 2, multiple; for strictures grad-
ing was considered 0, absent; 1, light; 2, moderate; and 3 accentuated
with proximal dilatation. For ulcer grading the scoring was 0, absent;
1, linear ulcer b 1 cm; 2, two linear ulcers b 1 cm; and 3, numerous
ulcers N 1 cm; and for thickness of the colon wall, 0, b1 mm; 1, 1 to
3 mm; and 2, N3 mm; total score ranging from 0 to 10 [37].
2.6. Histological inﬂammatory scores of the colon
Specimens were ﬁxed in 40 g/l formaldehyde saline, embedded in
parafﬁn, cut into 5-μm sections, stained with haematoxylin-eosin
stain, and examined microscopically by two independent observers.
The following histological parameters were studied: ulceration, hyper-
plasia, and inﬂammatory inﬁltrate. For both inﬂammatory inﬁltrate
and hyperplasia, grading was considered: 3, severe; 2, moderate; 1,
mild; and 0, absent. For ulcers, gradingwas: 4, diffuse glandular disrup-
tion or extensive deep ulceration; 3, glandular disruption or focal deep
ulceration; 2, diffuse superﬁcial ulceration; 1, focal superﬁcial ulcera-
tion; and 0, absent [39].
2.7. Assessment of collagen deposition in the colon
Specimens were ﬁxed in 40 g/l formaldehyde saline, embedded in
parafﬁn, and cut into 5-μm sections. The phosphomolibidic acid picro-
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different areas per tissue section were analyzed under light microscopy
connected to a computer-assisted image analyzer.2.8. Assessment of goblet cells in the colonic mucosa
The periodic acid of Schiff (PAS)was used to stain goblet cells within
the intestinal epithelium. The density of goblet cells was deﬁned as the
percentage of PAS-positive cells within at least 500 epithelial cells in the
crypts and in the surface epithelium of longitudinally sectioned colonic
pits.2.9. Assessment of T-cells, macrophages, and the expression of P2X7-R,
NF-kappa B, and p-Erk in the colon
For this set of experiments, parafﬁn sectionswere used to character-
ize the expression of P2X7-R and activation of intracellular signaling
pathways, by using the indirect immunoperoxidase technique. Immu-
nohistochemical staining was carried out using the following primary
antibodies: mouse monoclonal anti-rat ED1 antibody (Serotec Ltd.,
Oxford, UK) to macrophages; mouse monoclonal anti-rat CD3 antibody
(PC3/188) to lymphocytes; rabbit polyclonal anti-P2X7-R, mouse
monoclonal anti-rat p65 (F-6) to NF-kappa B; and mouse monoclonal
anti-rat P-ERK1/2 to phosphorylated ERK (all from Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA). Brieﬂy, serial sections of 5 μm were
immersed in 3% hydrogen peroxide in methanol for 10 min to block
endogenous peroxidase activity. After rinsing in phosphate-buffered
saline (PBS) containing 0.5% Tween 20 for 10 min, tissue sections
were incubated with no immune horse serum for 30 min and, subse-
quently, with the respective monoclonal antibody in a humidiﬁed
chamber overnight, at room temperature. Two sections from each sam-
ple were incubated with either PBS alone or mouse monoclonal IgG1
(concentration-matched) (Dako A/S, Glostrup, Denmark) and served
as negative controls. After rinsing in PBS for 10 min, all tissue sections
were incubated for 30 min with a goat anti-mouse peroxidase conju-
gate (Zymed Laboratories Inc., San Francisco, CA). Additional rinsing
was followed by developmentwith a solution containing hydrogen per-
oxide and diaminobenzidine, dehydrated, and arranged in histological
mounting medium.2.10. Assessment of apoptosis in the colon
To determine apoptosis, fragmented DNA was stained by the termi-
nal deoxynucleotidyltransferase (TdT)-mediated dUDP-biotin nick end
labeling (TUNEL) assay, with the TACS TM TdT kit — in situ apoptosis
detection kit (R&D Systems, Minneapolis, MN, USA). Parafﬁn sections
were ﬁrst deparafﬁnized, incubated with proteinase K solution for
15 min at room temperature, and then immersed in hydrogen peroxide
to block endogenous peroxidase activity. After rinsing, slideswere incu-
bated with the TdT labeling buffer for 5 min. This step was followed by
the incubation with the labeling reaction mix containing TdT enzyme
for 1 h at 37 °C. The biotinylated nucleotides incorporated to DNA
fragments were detected using a streptavidin horseradish peroxidase
conjugate. A second section of each sample, incubated without TdT
enzyme, constituted the negative controls. Positive controls were pre-
pared by treating samples with TACS-nuclease. After being rinsed in
PBS, all sections were developed with a solution containing hydrogen
peroxide and diaminobenzidine. Preparations were lightly counter-
stained in Harris's haematoxylin, dehydrated, and mounted in
Permount (Fisher Scientiﬁc, Pittsburgh, PA, USA). Morphologically
preserved TUNEL-positive cells and apoptotic bodies were referred
to as apoptotic cells and determined by using predeﬁned measure-
ments in the computer-assisted image analyser in conjunction with
careful evaluation of morphologic criteria.2.11. Quantitative assessment of colon sections
Quantitative analysis of tissue sections (under lightmicroscopy)was
carried out using a computer-assisted image analyser (Leica QWin Plus
V 3.5.1, LeicaMicrosystems Ltd, Switzerland). The density of collagen ﬁ-
berswas deﬁned by the area positively stained for collagen in relation to
total intestinal tissue per millimeter-squared using an imaging analysis
system at (×100magniﬁcation). Any epithelial and lamina propria cells
exhibiting identiﬁable reactivity distinct from background were
regarded as positive. In the immunoperoxidase studies, percentages of
the different cell subsets or apoptotic cells were deﬁned by the number
of immunoreactive cells in relation to total cells (immunoreactive and
non-immunoreactive cells) in the lamina propria (counted in at least
ten different areas), or in at least 500 epithelial cells in the crypts and
in the surface epithelium of longitudinally sectioned colonic crypts.
The results of the quantitative analysis of T cells and macrophages
were expressed as cell numbers per mm2 lamina propria. Two indepen-
dent observers who were unaware of the experimental data examined
all tissue sections and captured images.
2.12. Myeloperoxidase activity assessment
Colonic samples were frozen at −80 °C until the extraction of
myeloperoxidase (MPO) when they were homogenized in potassi-
um phosphate buffer (pH 6.0), freeze and defrost twice, homoge-
nized again in the potassium phosphate buffer (pH6.0) containing
0.5% hexadecyltrimethyl-ammonium bromide (Sigma Chemical Co.,
St. Louis, MO, USA), and centrifuged at 40.000 g for 30 min at 4 °C.
The supernatants were discarded and the insoluble pellets were re-
homogenized in the potassium phosphate buffer (pH 6.0) contain-
ing 0.5% hexadecyltrimethyl-ammonium bromide. Ten microliters
of the supernatants was added to a 96-well plate containing 290 μl
of 50 mM potassic PBS (pH 6,0), 3 μl of substrate solution, contain-
ing 20 mg/ml o-dianisidine (Sigma Chemical Co., St. Louis, MO,
USA), and 3 μl of H2O2 (20 mM). The plate components were rapidly
mixed and the absorbance was determined at 460 nm for 1 minwith
a spectrophotometer. MPO activity was measured by a standard curve
of the samples in units of MPO/mg of colonic samples. The total protein
content of the biopsy specimenswas estimated by the Pierce® BCA pro-
tein assay kit (Thermo Scientiﬁc, Rockford, IL, USA), and used for nor-
malizing the results.
2.13. Organ culture and cytokine measurements
Colonic explants were cultured in RPMI 1640 medium supplement-
ed with 10% fetal calf serum (Gibco-Invitrogen, Carlsbad, CA, USA),
2 mM L-glutamine, 50 μM2-mercaptoethanol, 10 mMHEPES, penicillin
(100 killiunits/l) and streptomycin (100 mg/l) (all from Sigma Chemi-
cal Co., St. Louis, MO, USA) for 24 h at 37 °C in a 5% CO2 humidiﬁed
incubator. Samples were centrifuged and the supernatants used for
the measurement of the concentration of cytokines TNF-α, IL-1β (both
from Peprotech Inc., Rocky Hill, NJ, USA), TGF-β (R&D Systems, MN,
USA), and IL-10 (Invitrogen, Camarillo, CA, USA) by commercial sen-
sitive enzyme-linked immunosorbent assay (ELISA) method. The
total protein content of the biopsy specimens was estimated by the
bicinchoninic acid (BCA) method, Pierce® BCA protein assay kit
(Thermo Scientiﬁc, Rockford, IL, USA), and used for normalizing
the results. The minimum detectable concentration of rat TNF-α,
IL-1β, TGF-β, and IL-10 was less than 5.0 pg/ml.
2.14. Statistical analysis
Statistical analyses were performed using the statistical software
SPSS forWindows (Version 10.1, SPSS Inc., 1989–1999, USA). Statistical
differences among the experimental groups were evaluated with the
one-way ANOVA on ranks test in which pairwise multiple comparisons
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was set at p b 0.05.2.15. Ethical considerations
The institutional animal care committee of the Federal University of
Rio de Janeiro approved the care and use of animals, as well as proce-
dures reported in this study (approval number # 83/09), in accordance
with the guidelines of the International Care and Use Committee of the
National Institutes of Health, and Guide for the Care and Use of Labora-
tory Animals (National Research Council-USA, 1996).3. Results
In a preliminary study, we investigated the potential therapeutic
effect of P2X7-R blockade using BBG on the TNBS-induced colitis
model. All TNBS/ethanol-induced animals developed a severe colitis,
characterized by diarrhea and weight loss, and no beneﬁcial effect
was seen after treatment with IP- or IC-BBG, administered on day 4
after induction (Fig. S1).Fig. 1. Effect of P2X7-R blockade with BBG on the clinical and colonoscopic parameters of the c
tered at 40 mg/kg at days–1 and 4. Following TNBS-induction, animals presented a progressive
treatedwith IP-BBG (* p b 0.007; ** p b 0.007) (A). Colonoscopic imagingwas obtained after col
rectal saline enemas, and intraperitoneal administration of vehicle in TNBS-induced animals. An
tion measured by the endoscopic score, in contrast to vehicle-treated animals (B,C). Values are3.1. Systemic blockade of P2X7-R with BBG attenuates TNBS-induced colitis
Next, we investigated the prophylactic effect of P2X7-R block-
ade, administering BBG one day prior to colitis induction. Follow-
ing TNBS-induction, animals presented a progressive weight loss
compared with controls on day 2 (p b 0.001), day 4 (p b 0.007),
and day 7 (p b 0.006); and compared to animals treated with intra-
peritoneal (IP) brilliant blue-G (BBG) on day 4 (p b 0.007), and day
7 (p b 0.007) (Fig. 1A). Colonoscopy was performed for assessing
the severity of colitis and for the detailed analysis of mucosal
changes following the different treatments. In control experi-
ments, colonoscopy was performed following intra-rectal saline
enemas, and intraperitoneal or intracolonic administration of vehi-
cle in TNBS-induced animals. TNBS-induced animals treated with
IP-BBG signiﬁcantly attenuated the endoscopic score compared to
animals treated with IC-BBG (p b 0.001), IP-vehicle (p = 0.001),
and IC-vehicle (p = 0.001). Colonoscopic imaging was obtained
after colitis induction at day 7 (Fig. 1B,C).
Following colonoscopic examinations, animals were euthanized, the
abdominal cavity was surveyed, and the colon was removed and
opened for the macroscopic analysis. TNBS-induced colitis manifested
predominantly as continuous inﬂammatory lesions in the distal colon.olitis model. Intraperitoneal (IP)- or intra-colonic (IC)-brilliant blue G (BBG) was adminis-
weight loss comparedwith controls (#p b 0.001; ## p b 0.007); and compared to animals
itis induction at day 7. In control experiments, colonoscopywas performed following intra-
imals treatedwith IP- (p b 0.002) but not IC-BBG, signiﬁcantly blunted colonic inﬂamma-
mean ± S.E.M. of 6–10 animals per group. Signiﬁcant values are presented.
69C.C. Marques et al. / Biochimica et Biophysica Acta 1842 (2014) 65–78Involved areas of the colon presented mucosal edema, ulceration, and
evidence of transmural inﬂammation. Animals treated with prophylac-
tic IP-BBG showed less inﬂammation compared to animals treated with
IC-BBG, IP-vehicle, and IC-vehicle (p b 0.001) (Fig. S2A,B).
3.2. Systemic blockade of P2X7-R with BBG attenuates tissue injury from
TNBS-induced colitis
Morphological changes of HE-stained sections were predominantly
detected in the distal colon of TNBS-induced animals. TNBS-colitis was
characterized by an intense cellular inﬁltration, predominantly of
mononuclear cells, compatible with a Th1-mediated immune response.
Treatment with prophylactic IP-BBG protected animals from full
development of TNBS-colitis, showing signiﬁcantly lower micro-
scopic damage scores compared to animals treated with IC-BBG,
IP-vehicle, and IC-vehicle (p b 0.001) (Fig. 2A,B and Fig. S3). Next,
colon samples of each animal were homogenized and protein was
extracted for analyzing the myeloperoxidase activity. Colon sam-
ples from IP-BBG-treated animalsmaintained low levels of MPO activity
comparable to controls, andwere signiﬁcantly lower compared to thoseFig. 2. Effect of P2X7-R blockade with BBG on histological parameters in the colon and myelop
(IP)- or intra-colonic (IC)-brilliant blueG (BBG)was administered at 40 mg/kg at days–1 and 4.
intra-colonic administration of vehicle, and intra-rectal saline enemas. Colonic samples were sc
Animals treated with IP-BBG showed signiﬁcantly less inﬂammation measured by histologic p
mals (p b 0.001). Values are mean ± S.E.M. of 6–10 animals per group. Signiﬁcant values are
showed signiﬁcantly lower levels following IP-BBG compared to IC-BBG- (p = 0.005), IP-vehi
medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges offrom animals treated with IC-BBG (p = 0.005), IP-vehicle (p = 0.005),
and IC-vehicle (p = 0.012) (Fig. 2C).
Collagen deposition in the colonic tissue was assessed by tissue
staining, and collagen ﬁbers showed a marked disorganization, being
diffusely distributed throughout the colon wall. Animals treated with
intraperitoneal brilliant blue-G (IP-BBG) presented signiﬁcantly lower
levels of collagen deposition compared to animals treated with
IP-vehicle (p = 0.003), and IC-vehicle (p = 0.009) (Fig. 3A,B and
Fig. S4A). The number of goblet cells was expressed as the percent-
age of positive cells in at least 500 cells of the colonic epithelium. In
animals treated with IP-BBG densities of goblet cells were similar
to those of the normal control group, but signiﬁcantly lower com-
pared to those of animals treated with IP-vehicle (p = 0.003),
and IC-vehicle (p = 0.009) (Fig. 3C,D and Fig. S4B).
3.3. Systemic blockade of P2X7-R with BBG attenuates macrophage and
T-cell inﬁltration in TNBS-induced colitis
To further characterize the lamina propria cellular inﬁltration at day
7 of colitis-induction, we investigated the densities of macrophages anderoxidase activity in the colon. Parafﬁn sections were stained with HE (A). Intraperitoneal
In control experiments, histological evaluationwasperformed following intraperitoneal or
ored according to histological parameters described in the Materials and methods section.
arameters compared to animals treated with IC-BBG (p b 0.001), and vehicle-treated ani-
presented. Length bars represent 20 μm (B). The myeloperoxidase activity in the colon
cle- (p = 0.005), and IC-vehicle- (p = 0.012) treated animals. Horizontal bars represent
6–10 animals per group. Signiﬁcant values are presented (C).
Fig. 3. Effect of P2X7-R blockadewith BBG on collagen deposition in the colon and the density of goblet cells. Parafﬁn sectionswere stainedwith phosphomolibidic acid-picrosirius red dye
(A) and periodic acid-Schiff (C). Intraperitoneal (IP)- or intra-colonic (IC)-brilliant blue G (BBG)was administered at 40 mg/kg at days –1 and 4. In control experiments, histological eval-
uation was performed following intraperitoneal or intra-colonic administration of vehicle, and intra-rectal saline enemas. Density of collagen ﬁbers was determined by a computerized
image analysis system. Animals treated with intraperitoneal brilliant blue-G (IP-BBG) showed signiﬁcantly less collagen deposition compared to IP-vehicle (p = 0.003), and IC-
vehicle- (p = 0.009) treated animals (B). The number of goblet cells was expressed as the percentage of positive cells in at least 500 cells of the colonic epithelium. Animals treated
with IP-BBG showed signiﬁcantly lower densities of goblet cells compared to IC-BBG (p = 0.002), IP-vehicle (p b 0.001), and IC-vehicle (p = 0.012) -treated animals. Horizontal bars
represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges of 6–10 animals/group (D). Length bars represent 20 μm.
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treated with prophylactic IP-BBG showed signiﬁcantly less macrophages
in the colonic lamina propria compared to those from animals treated
with IC-BBG (p = 0.001), IP-vehicle (p = 0.001), and IC-vehicle
(p = 0.004) (Fig. 4A,B and Fig. S5A). The density of lamina propria T-
cells was also signiﬁcantly lower in animals treated with prophylactic
IP-BBG compared to animals treated with IC-BBG (p b 0.001), IP-vehicle
(p = 0.001), and IC-vehicle (p = 0.041) (Fig. 4C,D and Fig. S5B).3.4. Systemic blockade of P2X7-R with BBG blunts P2X7-R expression and
attenuates apoptosis in TNBS-induced colitis
Animals treated with prophylactic IP-BBG showed a signiﬁcantly
lower expression of the P2X7-R both in the epithelium and lamina
propria compared to vehicle-treated animals (p b 0.004). When
analyzing the epithelial layer only, IP-BBG treated animals also
showed a signiﬁcantly lower expression compared to animals
Fig. 4. Effect of P2X7-R blockadewith BBG onmacrophages and T-cell inﬁltrationwithin the colon.Macrophages (A) and T-cells (C)were determined by indirect immunoperoxidase stain-
ing of parafﬁn sections. Intraperitoneal (IP)- or intra-colonic (IC)-brilliant blue G (BBG)was administered at 40 mg/kg at days –1 and 4. In control experiments, evaluationwas performed
following intraperitoneal or intra-colonic administration of vehicle, and intra-rectal saline enemas. Percentages of macrophages and T-cells in the colonicmucosawere analyzed in at least
10 different areas per tissue section. Animals treated with IP-BBG showed signiﬁcantly less macrophages (p b 0.005) (B) and T-cells (p b 0.05) (D) compared to IC-BBG-, IP-vehicle-, IC-
vehicle-treated animals. Horizontal bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges of 6–10 animals/group. Length bars repre-
sent 20 μm.
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and Fig. S6A). In regard to apoptosis, animals treated with IP-BBG
showed signiﬁcantly lower rates in the epithelial compartment
compared to IC-BBG-, IP-vehicle-, and IC-vehicle- (p b 0.024)
treated animals. In the lamina propria, the apoptotic rates were
signiﬁcantly higher in all TNBS-induced animals, and apparently
were not affected by BBG treatment (Fig. 5C,D and Fig. S6B).3.5. Systemic blockade of P2X7-R with BBG attenuates inﬂammatory
responses in TNBS-induced colitis
Next, we investigated whether the prophylactic blockade of P2X7-R
could affect the production of inﬂammatory mediators mechanistically
involved in intestinal inﬂammation. In animals treated with IP-BBG
TNF-α levels were similar to those of the normal control group, but
Fig. 5. Effect of P2X7-R blockade with BBG on P2X7-R expression and apoptotic rates within the colon. P2X7-R was determined by indirect immunoperoxidase staining (A) and
apoptotic cells were detected by the TUNEL assay (C). Intraperitoneal (IP)- or intra-colonic (IC)-brilliant blue G (BBG) was administered at 40 mg/kg at days –1 and 4. In con-
trol experiments, evaluation was performed following intraperitoneal or intra-colonic administration of vehicle, and intra-rectal saline enemas. Percentages of P2X7-R-
positive cells and apoptotic cells in the colonic epithelium and in the lamina propria were analyzed in at least 10 different areas per tissue section. Animals treated with
IP-BBG showed signiﬁcantly lower expression of P2X7-R compared to IC-BBG-, IP-vehicle-, IC-vehicle-treated animals in the epithelium (p b 0.002) and in the lamina propria
(p b 0.009) (B). Animals treated with intraperitoneal brilliant blue-G (IP-BBG) showed signiﬁcantly lower apoptotic rates compared to IC-BBG-, IP-vehicle-, IC-vehicle-
treated animals within the epithelium (p b 0.024) (D). Horizontal bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges
of 6–10 animals/group. Length bars represent 20 μm.
72 C.C. Marques et al. / Biochimica et Biophysica Acta 1842 (2014) 65–78signiﬁcantly lower compared to those of IC-BBG-, IP-vehicle-, and
IC-vehicle- (p b 0.043) treated animals, which presented a ~5-fold
increase in TNF-α levels. Similarly, levels of IL-1β were signiﬁcantly
lower in animals treated with IP-BBG than in animals treated with
IC-BBG, IP-vehicle, and IC-vehicle (p b 0.003) (Fig. 6A,B).
In regard to TGF-β production, here we show a ~2-fold increase
following TNBS induction, but levels did not change signiﬁcantly
after BBG-treatment, independent of the route of administration
(Fig. 6C). Similarly, levels of the anti-inﬂammatory cytokine IL-10
did not change signiﬁcantly after BBG-treatment compared with
the other groups (Fig. 6D).3.6. Systemic blockade of P2X7-R with BBG blunts NF-kappa B andMAP ki-
nase activation
In order to investigate the intracellular signaling pathways most
likely to be related to P2X7-R, we analyzed the expression and tissue
distribution of NF-kappa B and phosphorylated-Erk.
NF-kappa B activation wasmeasured by the nuclear translocation of
the p65 subunit. Animals treated with prophylactic IP-BBG showed a
signiﬁcantly less nuclear translocation of NF-kappa B in the colonic mu-
cosa, compared to IC-BBG- (p b 0.001), IP-vehicle- (p b 0.001), and IC-
vehicle- (p b 0.018) treated animals (Fig. 7A,B and Fig. S7A).
Fig. 6. Effect of P2X7-R blockadewith BBG on cytokine production in the inﬂamed colon. Colonic explants were cultured for 24 h at 37 °C. After centrifugation, supernatants were used for
measurement of the concentration of cytokines by an ELISAmethod for rat TNF-α (A), IL-1β (B), TGF-β (C), and IL-10 (D). Intraperitoneal (IP)- or intra-colonic (IC)-brilliant blue G (BBG)
was administered at 40 mg/kg at days –1 and 4. Animals treated with intraperitoneal brilliant blue-G (IP-BBG) presented signiﬁcantly lower levels of TNF-α (p b 0.043) and IL-1 β
(p b 0.003) production compared to intra-colonic BBG (IC-BBG)-, IP-vehicle-, and IC-vehicle-treated animals. No signiﬁcant differences were detected in animals treated with BBG for
TGF-β and IL-10 compared to the other experimental groups. Values are expressed as picogram of cytokine/ml of culture supernatant, and normalized by protein contents. Horizontal
bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges of 6–10 animals/group.
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IP-BBG showed a signiﬁcantly lower expression of the p-ERK in
the epithelium (p = 0.005) and lamina propria (p = 0.049), com-
pared to IC-BBG-, IP-vehicle, and IC-vehicle-treated animals, respective-
ly (Fig. 7C,D and Fig. S7B).
3.7. Systemic blockade of P2X7-R with A740003 attenuates TNBS-induced
colitis
In order to further conﬁrm the favorable results obtained with IP-
BBG, we next investigated another selective inhibitor of P2X7-R.
TNBS-induced animals treated with prophylactic IP-A740003 showed
signiﬁcantly lower endoscopic scores compared to vehicle-treated ani-
mals (p = 0.005) (Fig. 8A). Similar to the effect observed with IP-BBG,
prophylactic administration of IP-A740003 also protected animals
from full development of TNBS-colitis, showing signiﬁcantly lowerhistological damage scores compared to vehicle-treated animals
(p = 0.034) (Fig. 8B).
4. Discussion
Despite all the information accumulated in theﬁeld of IBDpathogen-
esis, translating scientiﬁc knowledge into practice is still a complex pro-
cess, and current therapies available for the patients possess limited
effectiveness and the side effects are still a major concern [41,42]. In
CD, the most recent approved therapies consist of potent anti-
inﬂammatory agents directed towards the induction of remission
[43,44]. However, maintaining the remission in CD constitutes a partic-
ular challenge, which usually requires the long-term administration of
potentially harmful immunosuppressant and/or biological agents
[45,46]. Therefore, the investigation of new therapeutic alternatives
for dampening early events that could be responsible for compromising
Fig. 7. Effect of P2X7-R blockade with BBG onNF-kappa B and p-Erk activation in the colon. NF-kappa Bwas determined by indirect immunoperoxidase staining usingmouse monoclonal
anti-rat p65 (A). Percentages of cells with nuclear NF-kappa B-staining (NF-kappa B-positive cells) in the colonicmucosawere analyzed in at least 10 different areas per tissue section. Erk
was determined by indirect immunoperoxidase staining using mouse monoclonal anti-rat P-ERK1/2 (C). Percentages of cells with p-Erk staining (p-Erk-positive cells) in the colonic mu-
cosa were analyzed in at least 10 different areas per tissue section, both in the epithelium and lamina propria. Intraperitoneal (IP)- or intra-colonic (IC)-brilliant blue G (BBG) was admin-
istered at 40 mg/kg at days –1 and 4. In control experiments, evaluationwas performed following intraperitoneal or intra-colonic administration of vehicle, and intra-rectal saline enemas.
Animals treatedwith IP-BBG showed signiﬁcantly lower expression of NF-kappa B in the colon compared to IC-BBG- (p b 0.001) and IP-vehicle- (p b 0.001), and IC-vehicle- (p = 0.018)
treated animals (B). P-Erk positive cells showed a signiﬁcantly lower expression in IP-BBG-treated animals compared to IC-BBG-, IP-vehicle-, IC-vehicle-treated animals in the epithelium
(p b 0.005) and in the lamina propria (p b 0.049) (D). Horizontal bars represent medians, boxes represent the 25th and 75th percentiles, and vertical bars represent ranges of 6–10 an-
imals/group. Length bars represent 20 μm.
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inﬂammation seems to be critically important.
In this study, we tested the therapeutic effect of P2X7-R blockade in
TNBS-induced colitis, a murine experimental model of CD. Of note, we
compared different routes of administration and tested the potential
beneﬁcial effects of distinct P2X7-R antagonists in experimental colitis.In respect of efﬁcacy, the systemic blockade of P2X7-R attenuated the
weight loss, while consistently stabilized the colonoscopic and histolog-
ic scores of TNBS-induced animals, after one week of treatment. In
particular, we demonstrated that prophylactic treatment with the
P2X7-R antagonist attenuated the collagen deposition and the in-
ﬂammatory cell inﬁltration, preserved the mucous-producing goblet
Fig. 8. Effect of P2X7-R blockadewith A740003 on the colonoscopic parameters and histological parameters in the colitismodel. Colonoscopic imagingwas obtained after colitis induction
at day 7. In control experiments, colonoscopywas performed following intra-rectal saline enemas, and intraperitoneal administration of vehicle in TNBS-induced animals. Animals treated
with intraperitoneal (IP) A740003, showed signiﬁcantly less inﬂammation as assessed by colonoscopy, in contrast to vehicle-treated animals (p = 0.005). Values aremean ± S.E.M. of 5–6
animals per group. Signiﬁcant values are presented (A). Parafﬁn sections were stained with HE. Intraperitoneal (IP)-A740003 was administered at 16 mg/kg at day –1. In control experi-
ments, histological evaluationwas performed following intraperitoneal administration of vehicle, and intra-rectal saline enemas. Colonic sampleswere scored according to histological pa-
rameters described in the Materials and methods section. Animals treated with IP-A740003 showed signiﬁcantly less inﬂammation measured by histologic parameters compared to
vehicle-treated animals (p = 0.034). Values are mean ± S.E.M. of 5–6 animals per group. Signiﬁcant values are presented (B). Length bars represent 20 μm.
75C.C. Marques et al. / Biochimica et Biophysica Acta 1842 (2014) 65–78cells, and stabilized the rate of epithelial apoptosis and the local pro-
duction of proinﬂammatory cytokines. In addition, we demonstrated
a route-dependent differential effect considering that the therapeu-
tic beneﬁt occurred only following systemic blockade of the P2X7-R.
Recent studies also addressed the potential role of P2X7 signaling in
intestinal inﬂammation. In one of them, investigators identiﬁed ATP/
P2X7-mediated mast cell activation, as a critical mechanism for the
development of acute TNBS-colitis in mice [47]. In another one, with a
nontransgenicmodel of T cell-mediated chronic colitis, the repeated ad-
ministration of the P2X antagonist periodate-oxidized 2′,3′-dialdehyde
ATP (oATP) attenuated the intestinal inﬂammation [26]. The P2X7-Rs
have a relatively low constitutive expression in the mammalian gastro-
intestinal epithelium [48,49] but have been shown to be up-regulated
following exposure to a signature molecule of the Th1-type of immune
response, IFN-gamma [33]. Therefore, as expected for the TNBS-colitis,
an experimental model characterized as a Th1-type immune response
with the resulting production of pro-inﬂammatory mediators and
cytokines, including IFN-gamma [50], we detected a remarkable
over-expression of P2X7-R in the inﬂamed colon. Consequently, we
ﬁrst attempted to treat the colitic animals through P2X7-R blockade
using BBG. However, blocking P2X7-R after the full development of
colitis apparently did not change the severity of inﬂammation. On
the other hand, a dramatic beneﬁcial effect was seen upon the pro-
phylactic blockade of the P2X7-R. Thus, considering the different
approaches, our results and those of others, appear to present com-
plementary information, conﬁrming the complex dynamics and in-
tricate mechanisms underlying the pathologic process of intestinal
inﬂammation mediated by P2X7 signaling.
In respect of the antagonists used in this study, BBG and A-740003
concentrations were based on the evidence of systemic inhibition of
the P2X7-R as demonstrated in previous works [35,51–53]. However,
these antagonists belong to different classes with distinct chemicalfeatures. BBG has been described as having slow rates of association
and not competitively blocking agonist activation of P2X receptors
[54,55]. On the other hand, since the P2X7/pannexin-1 axis appears to
play a role in enteric neurocytotoxicity during colitis [56] and that
BBG can also block pannexin-1 [57], and other P2 receptors in higher
doses ([52], it is possible that BBG may also act independently of
P2X7-R. In contrast, A-740003 has an increased afﬁnity for selectively
binding and competitively blocking the P2X7-R, with less time-
dependent changes in potency compared with the other antagonists,
providing awider therapeuticwindow [35,58]. In addition, this selective
antagonist has similar afﬁnity for blocking P2X7-R-mediated calcium
inﬂux, pore formation and the release of IL-1β [35,59]. Therefore, the
successful prophylactic treatment with A-740003 corroborates the
results with BBG, and reinforces the idea of P2X7-R as a therapeutic tar-
get in intestinal inﬂammation.
In regard to the anti-inﬂammatory effects of P2X7-R blocking
agents, this study demonstrates the resulting down-regulation of the
Th1-driven inﬂammatory response in an experimental model of colitis.
An abnormally high production of proinﬂammatory cytokines of the
Th1-type of immune response is characteristic of TNBS-induced colitis
[60] and of CD, where TNF-α, in particular, has been regarded as a key
molecule for the development of the characteristic gastrointestinal
inﬂammation [61]. IL-1β is another proinﬂammatory cytokine of the
Th1-type of immune response, involved in the immediate innate
immune responses to bacterial products [17,62], and also the cytokine
most tightly controlled by the P2X7 signaling [17]. In this study, the
prophylactic systemic blockade of the P2X7-R stabilized both TNF-α
and IL-1β in low levels, in contrast to the high levels observed in the
colitic animals. On the other hand, the anti-inﬂammatory cytokines an-
alyzed in this study, IL-10 and TGF-β were not affected by the P2X7-R
blockade. This is in agreement with the notion that signaling through
P2X7-R is involved in the production of pro-inﬂammatory cytokines,
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phages by extra-cellular ATP.
Intestinal ﬁbrosis constitutes a common complication of CD, in
which the transmural inﬂammation leads to an excessive extracellular
matrix deposition [63,64]. Although the exact mechanisms underlying
ﬁbrogenesis in CD are yet to be determined, evidence indicates an im-
portant role for TGF-beta [65,66]. Here, we showed that the prophylac-
tic blockade of the P2X7-R prevented the collagen deposition in TNBS-
induced colitis, but the levels of TGF-beta did not change concomitantly.
Alternative mechanisms inducing ﬁbrogenesis, independent of TGF-
beta, have been proposed in the context of intestinal inﬂammation.
For instance, TNF-α, has been shown to stimulate the production ofme-
talloproteinases and collagen by myoﬁbroblasts and ﬁbroblasts [67].
Hence, it is likely that immunomodulatory effects of the P2X7-R block-
ade could also play a role in preserving the extracellular matrix in the
TNBS-colitis model, through the down-regulation of pro-inﬂammatory
cytokines. Similar to ourﬁndings in the colon, a recent studyusing a pul-
monary ﬁbrosis model demonstrated that extracellular ATP is also a key
mediator of lung inﬂammation and ﬁbrosis [68]. In analogy to our
successful interventionwith the prophylactic but not the therapeutic
P2X7-R blockade, another study using an infectious colitis model
showed that only the early, but not the late antibiotic eradication
of the Salmonella typhimurium infection, effectively repressed in-
ﬂammation and ﬁbrosis [69]. This is consistent with the importance
of early events in tissue damage, such as the rapid release of ATP
from injured cells, in the triggering and ampliﬁcation of inﬂammation.
In experimental models of IBD and in human IBD, the activation and
nuclear translocation of NF-κB family members constitute critical ele-
ments in the control of the inﬂammatory process [10,60] including the
production of pro-inﬂammatory cytokines [70,71]. The strong inhibition
of NF-kappa B activation obtained with the prophylactic blockade of
P2X7-R in TNBS-induced animals, reinforces the ﬁndings of previous
studies suggesting a beneﬁcial effect for NF-kappa B inhibition in
preventing the development [72], as well as reversing established
TNBS-induced colitis [73]. Another important intracellular signaling
pathway in the control of the inﬂammatory response, the mitogen-
activated protein kinases (MAPKs), has also been associated with IBD
[74,75] and experimental colitis [34,76], and was recently shown to
be activated through P2X7-R signaling [77]. Here, we show that the
P2X7-R blockade also effectively inhibited ERK activation in the
intestinal mucosa. Thus, it is reasonable to suppose that the concom-
itant inhibition of ERK and NFkB within the lamina propria mononu-
clear cells inﬁltrating the intestinal mucosa reﬂects the wide range of
actions accomplished by the P2X7-R blockade. These results corrob-
orate the existence of a cross-talk betweenMAPKs and NFkB [77–79],
supporting a mechanistic cooperation of different signaling path-
ways for the control of inﬂammatory responses.
Intestinal epithelial cells exhibit a high cell turnover that is critical
for maintaining epithelial integrity and intestinal homeostasis. In this
sense, the P2X7-R appears as a potentially important physiologic mole-
cule since it has been implicated in cell proliferation, differentiation, and
cell death [80]. Nevertheless, the upregulation of the P2X7-R expression
has been described in different inﬂammatory states affecting diverse
organs and tissues [81,82]. In regard to the intestine, we previously
demonstrated that the P2X7-R expression increases following exposure
to IFN-gamma [33], via the production of reactive oxygen species [19]
and the phenomenon was also shown to favor apoptosis of intestinal
epithelial cells [18]. Furthermore, intestinal epithelial cells were also
shown to be capable of releasing ATP [83], suggesting that ATP may
additionally act as an autocrine mediator integrating and amplifying
P2X7 signaling. Together, these data corroborate the notion that under
pathological conditions P2X7-R may respond to ATP, triggering an
abnormally high release of proinﬂammatory cytokines, and excessive
induction of apoptosis. In our study, the increased expression of
P2X7-R in parallel with the highest rates of apoptosis observed in
the colitic animals, lends additional support to explain the dramaticmorphological changes secondary to an uncontrolled state of inﬂam-
mation. In this context, the drastic reduction in the number of highly
differentiated mucus-secreting cells may also result from the con-
comitant increase in apoptosis and P2X7-R expression in TNBS-
colitis. The abnormally increased apoptotic rates may further com-
promise the epithelial barrier, resulting in an excessive exposure
and permeability to luminal bacteria.
Taken together, these ﬁndings seem to indicate that after the full es-
tablishment of the inﬂammatory process, the mechanisms activated
downstream of P2X7-R may sustain and even amplify the response
through the cross-talk with converging and integrated signaling path-
ways. Hence, we speculate that the expression and activation of the
P2X7-R may efﬁciently constitute a ﬁne regulatory mechanism critical
in the early events associated with epithelial barrier dysfunction.
In conclusion, the up-regulation of epithelial P2X7-R in response to
TNBS-induced colitis is consistent with the involvement of P2 receptors
in ATP-induced inﬂammation and apoptotic cell death. Systemic admin-
istered P2X7-R antagonists are effective in the prophylactic treatment of
experimental colitis, probably due to a systemic anti-inﬂammatory
action, interfering with a stress-inﬂammation ampliﬁcation loop medi-
ated by P2X7-R. Taken together, these observationsmay implicate P2X7
signaling in the pathogenesis of inﬂammatory bowel disease, and the
P2X7-R blockade emerges as a promising novel therapy for human IBD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.10.012.
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